BELLEVUE, Wash.--(BUSINESS WIRE)--SCOLR Pharma, Inc. (AMEX: DDD) today reported financial results for the fiscal year ended December 31, 2006.
Total revenues increased significantly to $2.3 million for the year ended December 31, 2006, compared to $0.6 million for 2005, primarily as a result of $1.3 million of research and development income attributable to the Company’s agreement with Wyeth Consumer Healthcare, and increased royalty income of $0.2 million from its alliance with Perrigo. As previously reported, Perrigo has been successful in marketing its first CDT®-based sustained release nutritional product to a significant number of the nation’s largest retailers. Perrigo has introduced additional nutritional products which the Company believes will result in a higher level of royalty revenues during 2007.
